Clinical Trials Logo

Cognitive Dysfunction clinical trials

View clinical trials related to Cognitive Dysfunction.

Filter by:
  • Completed  
  • « Prev · Page 103

NCT ID: NCT00182065 Completed - Clinical trials for Heart Failure, Congestive

Heart Failure, Functional and Cognitive Decline, and Psychiatric Symptoms in Nursing Home Patients

Start date: March 1, 2004
Phase:
Study type: Observational

Heart failure is very common in the elderly, in whom it may lead to functional and intellectual problems. Functional problems include loss in the ability to perform basic tasks of daily living such as bathing or dressing. No studies have yet described the rate at which heart failure causes these problems to develop. This study aims to find out whether nursing home patients deteriorate more quickly with respect to function and intellect if they have heart failure. Participants will undergo a thorough health history and physical examination and will be followed every 3 months for up to a year. Over 30 nursing homes in Kitchener, Waterloo, Cambridge, and Hamilton, in South Central Ontario (Canada), are participating in this study. Every 3 months, participants will be reviewed with respect to function, intellect, mood and behaviours. Results between those with heart failure will be compared to those of people without heart failure. The results of this study will be used to plan further studies to see whether good treatment of heart failure can preserve function, intellect, and prevent depression and other mood problems.

NCT ID: NCT00176423 Completed - Schizophrenia Clinical Trials

Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia

Start date: May 2002
Phase: Phase 4
Study type: Interventional

The purpose of this study is to examine whether adjunctive galantamine is effective in the treatment of cognitive impairments in patients with schizophrenia.

NCT ID: NCT00161031 Completed - Schizophrenia Clinical Trials

Atomoxetine as an Adjunct to Novel Antipsychotic Medication in the Treatment of Cognitive Deficits of Schizophrenia

Start date: April 2004
Phase: N/A
Study type: Interventional

The purpose of this study is to: - To examine wether adjunctive atomoxetine is more effective thank placebo for neuropsychological measures of reaction time, motor speed, psychomotor speed, sustained attention, learning and memory, working memory, and executive functioning. To determine the effect size of atomoxetine on these neuropsychological measures for follow-up studies. - To determine if atomoxetine has short-term benefits for improving weight gain and other metabolic abnormalities associated with antipsychotics.

NCT ID: NCT00040443 Completed - Clinical trials for Mild Cognitive Impairment

Efficacy And Safety Of CX516 In Elderly Participants With Mild Cognitive Impairment.

Start date: April 2002
Phase: Phase 2
Study type: Interventional

Glutamate is fundamentally involved in learning and memory. Memory loss associated with mild cognitive impairment may be due to loss of glutamate receptors in the aging brain. There is evidence CX516 enhances brain activity by specifically targeting remaining glutamate receptors in the affected portions of the brain. This study will test the safety and efficacy of CX516 in the symptomatic treatment of participants with mild cognitive impairment.